Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A - biospace.com
Why now
Thesis: Telix buys ITM for $1.65B in radiopharma M&A
Catalyst to watch: Deal completion and synergies
Main risk: Integration or regulatory hurdles
Why it matters
$1.65B radiopharma acquisition signals continued biotech M&A appetite and sector consolidation.
Sources
- googlenews · news.google.com · 2026-09-21 13:19 UTC
- googlenews · news.google.com · 2026-09-21 13:19 UTC